Advertisement

Dexmedetomidine Infusion Therapy

  • Simon Zec
  • Antony Tharian
  • Kenneth D. Candido
  • Nebojsa Nick KnezevicEmail author
Chapter

Abstract

Dexmedetomidine (4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, is a highly potent, selective α2-adrenergic receptor agonist with sedative, analgesic and anxiolytic properties. Although primarily used for sedation in adult intensive care unit patients, novel applications have emerged in the literature, with favorable results in the prevention of delirium, acute postoperative pain, and opioid induced hyperalgesia, amongst others. Dexmedetomidine exerts its action by binding to α2A-, α2B-, and α2C-adrenoceptors, producing plasma concentration-dependent hypotension and bradycardia without respiratory depression.

Keywords

Dexmedetomidine Infusion Acute postoperative pain Complex regional pain syndrome Opioid-induced hyperalgesia Sedation in the ICU Delirium in ICU Drug withdrawal and weaning Awake fiberoptic intubation Procedural sedation Awake fiberoptic intubation 

References

  1. 1.
    Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000;59(2):263–8. discussion 9–70.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Weerink MAS, Struys M, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    US Food and Drug Administration. Precedex label. 1999. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021038s017lbl.pdf.
  4. 4.
    Weatherall M, Aantaa R, Conti G, Garratt C, Pohjanjousi P, Lewis MA, et al. A multinational, drug utilization study to investigate the use of dexmedetomidine (Dexdor(R)) in clinical practice in the EU. Br J Clin Pharmacol. 2017;83(9):2066–76.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    European Medicines Agency. Dexdor: EPAR – Product Information. 2018. Available from: https://www.ema.europa.eu/documents/product-information/dexdor-epar-product-information_en.pdf.
  6. 6.
    Hoy SM, Keating GM. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 2011;71(11):1481–501.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Tan JA, Ho KM. Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med. 2010;36(6):926–39.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Nazarian A, Christianson CA, Hua XY, Yaksh TL. Dexmedetomidine and ST-91 analgesia in the formalin model is mediated by alpha2A-adrenoceptors: a mechanism of action distinct from morphine. Br J Pharmacol. 2008;155(7):1117–26.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Arcangeli A, D’Alo C, Gaspari R. Dexmedetomidine use in general anaesthesia. Curr Drug Targets. 2009;10(8):687–95.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Correa-Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats. Anesthesiology. 1992;76(6):948–52.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    McKay BE, Lado WE, Martin LJ, Galic MA, Fournier NM. Learning and memory in agmatine-treated rats. Pharmacol Biochem Behav. 2002;72(3):551–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Reis DJ, Regunathan S, Golanov EV, Feinstein DL. Protection of focal ischemic infarction by rilmenidine in the animal: evidence that interactions with central imidazoline receptors may be neuroprotective. Am J Cardiol. 1994;74(13):25A–30A.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Khan ZPFC, Jones RM. Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 2002;54(2):146–65.CrossRefGoogle Scholar
  14. 14.
    Sullivan AF, Kalso EA, McQuay HJ, Dickenson AH. The antinociceptive actions of dexmedetomidine on dorsal horn neuronal responses in the anaesthetized rat. Eur J Pharmacol. 1992;215(1):127–33.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Mukaddam-Daher S, Gutkowska J. Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides. Braz J Med Biol Res. 2004;37(8):1239–45.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Haselman MA. Dexmedetomidine: a useful adjunct to consider in some high-risk situations. AANA J. 2008;76(5):335–9.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90(3):699–705.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Venn RM, Bradshaw CJ, Spencer R, Brealey D, Caudwell E, Naughton C, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia. 1999;54(12):1136–42.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth. 2001;87(5):684–90.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hsu YW, Cortinez LI, Robertson KM, Keifer JC, Sum-Ping ST, Moretti EW, et al. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology. 2004;101(5):1066–76.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1988;150(1–2):9–14.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Knezevic NN, Yekkirala A, Yaksh TL. Basic/translational development of forthcoming opioid- and nonopioid-targeted pain therapeutics. Anesth Analg. 2017;125(5):1714–32.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Al-Metwalli RR, Mowafi HA, Ismail SA, Siddiqui AK, Al-Ghamdi AM, Shafi MA, et al. Effect of intra-articular dexmedetomidine on postoperative analgesia after arthroscopic knee surgery. Br J Anaesth. 2008;101(3):395–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LH. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg. 2007;105(2):374–80.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Anttila M, Penttila J, Helminen A, Vuorilehto L, Scheinin H. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol. 2003;56(6):691–3.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Abdallah FW, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth. 2013;110(6):915–25.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Venn M, Newman J, Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med. 2003;29(2):201–7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30(12):2188–96.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Skrobik Y, Duprey MS, Hill NS, Devlin JW. Low-dose nocturnal dexmedetomidine prevents ICU delirium. A randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2018;197(9):1147–56.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Manchikanti L, Helm S 2nd, Fellows B, Janata JW, Pampati V, Grider JS, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9–38.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Donroe JH, Tetrault JM. Substance use, intoxication, and withdrawal in the critical care setting. Crit Care Clin. 2017;33(3):543–58.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology. 2003;98(2):575–7.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Finkel JC, Elrefai A. The use of dexmedetomidine to facilitate opioid and benzodiazepine detoxification in an infant. Anesth Analg. 2004;98(6):1658–9, table of contentsCrossRefGoogle Scholar
  34. 34.
    Finkel JC, Johnson YJ, Quezado ZM. The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children. Crit Care Med. 2005;33(9):2110–2.CrossRefGoogle Scholar
  35. 35.
    Baddigam K, Russo P, Russo J, Tobias JD. Dexmedetomidine in the treatment of withdrawal syndromes in cardiothoracic surgery patients. J Intensive Care Med. 2005;20(2):118–23.CrossRefGoogle Scholar
  36. 36.
    Zhou LJ, Fang XZ, Gao J, Zhangm Y, Tao LJ. Safety and efficacy of dexmedetomidine as a sedative agent for performing awake intubation: a meta-analysis. Am J Ther. 2016;23(6):e1788–e800.CrossRefGoogle Scholar
  37. 37.
    Hu R, Liu JX, Jiang H. Dexmedetomidine versus remifentanil sedation during awake fiberoptic nasotracheal intubation: a double-blinded randomized controlled trial. J Anesth. 2013;27(2):211–7.CrossRefGoogle Scholar
  38. 38.
    Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY, et al. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesth Analg. 2010;110(1):47–56.CrossRefGoogle Scholar
  39. 39.
    Jalowiecki P, Rudner R, Gonciarz M, Kawecki P, Petelenz M, Dziurdzik P. Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology. 2005;103(2):269–73.CrossRefGoogle Scholar
  40. 40.
    Jin S, Liang DD, Chen C, Zhang M, Wang J. Dexmedetomidine prevent postoperative nausea and vomiting on patients during general anesthesia: a PRISMA-compliant meta analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(1):e5770.CrossRefGoogle Scholar
  41. 41.
    Wang G, Zhang L, Lou S, Chen Y, Cao Y, Wang R, et al. Effect of dexmedetomidine in preventing postoperative side effects for laparoscopic surgery: a Meta-analysis of randomized controlled trials and trial sequential analysis (PRISMA). Medicine (Baltimore). 2016;95(10):e2927.CrossRefGoogle Scholar
  42. 42.
    Sottas CE, Anderson BJ. Dexmedetomidine: the new all-in-one drug in paediatric anaesthesia? Curr Opin Anaesthesiol. 2017;30(4):441–51.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Wang X, Deng Q, Liu B, Yu X. Preventing emergence agitation using ancillary drugs with sevoflurane for pediatric anesthesia: a network meta-analysis. Mol Neurobiol. 2017;54(9):7312–26.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Makkar JK, Bhatia N, Bala I, Dwivedi D, Singh PM. A comparison of single dose dexmedetomidine with propofol for the prevention of emergence delirium after desflurane anaesthesia in children. Anaesthesia. 2016;71(1):50–7.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Davy A, Fessler J, Fischler M, LE Guen M. Dexmedetomidine and general anesthesia: a narrative literature review of its major indications for use in adults undergoing non-cardiac surgery. Minerva Anestesiol. 2017;83(12):1294–308.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Ziemann-Gimmel P, Goldfarb AA, Koppman J, Marema RT. Opioid-free total intravenous anaesthesia reduces postoperative nausea and vomiting in bariatric surgery beyond triple prophylaxis. Br J Anaesth. 2014;112(5):906–11.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Hwang W, Lee J, Park J, Joo J. Dexmedetomidine versus remifentanil in postoperative pain control after spinal surgery: a randomized controlled study. BMC Anesthesiol. 2015;15:21.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Helander EM, Menard BL, Harmon CM, Homra BK, Allain AV, Bordelon GJ, et al. Multimodal analgesia, current concepts, and acute pain considerations. Curr Pain Headache Rep. 2017;21(1):3.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    American Society of Anesthesiologists Task Force on Acute Pain M. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012;116(2):248–73.CrossRefGoogle Scholar
  50. 50.
    Luo J, Min S. Postoperative pain management in the postanesthesia care unit: an update. J Pain Res. 2017;10:2687–98.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Tang C, Xia Z. Dexmedetomidine in perioperative acute pain management: a non-opioid adjuvant analgesic. J Pain Res. 2017;10:1899–904.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Lin TF, Yeh YC, Lin FS, Wang YP, Lin CJ, Sun WZ, et al. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. Br J Anaesth. 2009;102(1):117–22.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Wahlander S, Frumento RJ, Wagener G, Saldana-Ferretti B, Joshi RR, Playford HR, et al. A prospective, double-blind, randomized, placebo-controlled study of dexmedetomidine as an adjunct to epidural analgesia after thoracic surgery. J Cardiothorac Vasc Anesth. 2005;19(5):630–5.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Wang X, Liu W, Xu Z, Wang F, Zhang C, Wang B, et al. Effect of dexmedetomidine alone for intravenous patient-controlled analgesia after gynecological laparoscopic surgery: a consort-prospective, randomized, controlled trial. Medicine (Baltimore). 2016;95(19):e3639.CrossRefGoogle Scholar
  55. 55.
    Peng K, Zhang J, Meng XW, Liu HY, Ji FH. Optimization of postoperative intravenous patient-controlled analgesia with opioid-dexmedetomidine combinations: an updated meta-analysis with trial sequential analysis of randomized controlled trials. Pain Physician. 2017;20(7):569–96.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Fan W, Xue H, Sun Y, Yang H, Zhang J, Li G, et al. Dexmedetomidine improves postoperative patient-controlled analgesia following radical mastectomy. Front Pharmacol. 2017;8:250.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Tufanogullari B, White PF, Peixoto MP, Kianpour D, Lacour T, Griffin J, et al. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. Anesth Analg. 2008;106(6):1741–8.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Ge DJ, Qi B, Tang G, Li JY. Intraoperative dexmedetomidine promotes postoperative analgesia and recovery in patients after abdominal hysterectomy: a double-blind. Randomized Clinical Trial Sci Rep. 2016;6:21514.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Ge DJ, Qi B, Tang G, Li JY. Intraoperative dexmedetomidine promotes postoperative analgesia and recovery in patients after abdominal colectomy: a CONSORT-prospective, randomized, controlled clinical trial. Medicine (Baltimore). 2015;94(43):e1727.CrossRefGoogle Scholar
  60. 60.
    Rajan S, Hutcherson MT, Sessler DI, Kurz A, Yang D, Ghobrial M, et al. The effects of dexmedetomidine and remifentanil on hemodynamic stability and analgesic requirement after craniotomy: a randomized controlled trial. J Neurosurg Anesthesiol. 2016;28(4):282–90.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Naik BI, Nemergut EC, Kazemi A, Fernandez L, Cederholm SK, McMurry TL, et al. The effect of dexmedetomidine on postoperative opioid consumption and pain after major spine surgery. Anesth Analg. 2016;122(5):1646–53.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Liu Y, Liang F, Liu X, Shao X, Jiang N, Gan X. Dexmedetomidine reduces perioperative opioid consumption and postoperative pain intensity in neurosurgery: a Meta-analysis. J Neurosurg Anesthesiol. 2018;30(2):146–55.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Lee HS, Yoon HY, Jin HJ, Hwang SH. Can dexmedetomidine influence recovery profiles from general anesthesia in nasal surgery? Otolaryngol Head Neck Surg. 2018;158(1):43–53.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Le Bot A, Michelet D, Hilly J, Maesani M, Dilly MP, Brasher C, et al. Efficacy of intraoperative dexmedetomidine compared with placebo for surgery in adults: a meta-analysis of published studies. Minerva Anestesiol. 2015;81(10):1105–17.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Nama S, Meenan DR, Fritz WT. The use of sub-anesthetic intravenous ketamine and adjuvant dexmedetomidine when treating acute pain from CRPS. Pain Physician. 2010;13(4):365–8.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Zhou QQ, Imbe H, Zou S, Dubner R, Ren K. Selective upregulation of the flip-flop splice variants of AMPA receptor subunits in the rat spinal cord after hindpaw inflammation. Brain Res Mol Brain Res. 2001;88(1–2):186–93.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Lin JP, Chen CQ, Huang LE, Li NN, Yang Y, Zhu SM, et al. Dexmedetomidine attenuates neuropathic pain by inhibiting P2X7R expression and ERK phosphorylation in rats. Exp Neurobiol. 2018;27(4):267–76.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Sheehy KA, Finkel JC, Darbari DS, Guerrera MF, Quezado ZM. Dexmedetomidine as an adjuvant to analgesic strategy during vaso-occlusive episodes in adolescents with sickle-cell disease. Pain Pract. 2015;15(8):E90–7.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
  70. 70.
    Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alfonsi P, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000;93(2):409–17.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008;24(6):479–96.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Kaye AD, Chung KS, Vadivelu N, Cantemir C, Urman RD, Manchikanti L. Opioid induced hyperalgesia altered with propofol infusion. Pain Physician. 2014;17(2):E225–8.PubMedGoogle Scholar
  73. 73.
    Belgrade M, Hall S. Dexmedetomidine infusion for the management of opioid-induced hyperalgesia. Pain Med. 2010;11(12):1819–26.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Patch Iii RK, Eldrige JS, Moeschler SM, Pingree MJ. Dexmedetomidine as part of a multimodal analgesic treatment regimen for opioid induced hyperalgesia in a patient with significant opioid tolerance. Case Rep Anesthesiol. 2017;2017:9876306.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Santonocito C, Noto A, Crimi C, Sanfilippo F. Remifentanil-induced postoperative hyperalgesia: current perspectives on mechanisms and therapeutic strategies. Local Reg Anesth. 2018;11:15–23.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Lee C, Kim YD, Kim JN. Antihyperalgesic effects of dexmedetomidine on high-dose remifentanil-induced hyperalgesia. Korean J Anesthesiol. 2013;64(4):301–7.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Yu Z, Wu W, Wu X, Lei H, Gong C, Xu S. Protective effects of dexmedetomidine combined with flurbiprofen axetil on remifentanil-induced hyperalgesia: a randomized controlled trial. Exp Ther Med. 2016;12(4):2622–8.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Qiu H, Sun Z, Shadhiya F, Arulthas R, Priya GV, Christopher P, et al. The influence of dexmedetomidine on remifentanil-induced hyperalgesia and the sex differences. Exp Ther Med. 2018;16(4):3596–602.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Yuan Y, Sun Z, Chen Y, Zheng Y, Xie KL, He Y, et al. Prevention of remifentanil induced postoperative hyperalgesia by dexmedetomidine via regulating the trafficking and function of spinal NMDA receptors as well as PKC and CaMKII level in vivo and in vitro. PLoS One. 2017;12(2):e0171348.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Rodrigues AD, Roberts EM. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). Drug Metab Dispos. 1997;25(5):651–5.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Karol MD, Maze M. Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans. Best Pract Res Clin Anaesthesiol. 2000;14(2):261–9.CrossRefGoogle Scholar
  82. 82.
    Prommer E. Review article: dexmedetomidine: does it have potential in palliative medicine? Am J Hosp Palliat Care. 2011;28(4):276–83.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Savla JR, Ghai B, Bansal D, Wig J. Effect of intranasal dexmedetomidine or oral midazolam premedication on sevoflurane EC50 for successful laryngeal mask airway placement in children: a randomized, double-blind, placebo-controlled trial. Paediatr Anaesth. 2014;24(4):433–9.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Aantaa R, Jaakola ML, Kallio A, Kanto J. Reduction of the minimum alveolar concentration of isoflurane by dexmedetomidine. Anesthesiology. 1997;86(5):1055–60.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Jang YE, Kim YC, Yoon HK, Jeon YT, Hwang JW, Kim E, et al. A randomized controlled trial of the effect of preoperative dexmedetomidine on the half maximal effective concentration of propofol for successful i-gel insertion without muscle relaxants. J Anesth. 2015;29(3):338–45.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Buhrer M, Mappes A, Lauber R, Stanski DR, Maitre PO. Dexmedetomidine decreases thiopental dose requirement and alters distribution pharmacokinetics. Anesthesiology. 1994;80(6):1216–27.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Shah AN, Koneru J, Nicoara A, Goldfeder LB, Thomas K, Ehlert FA. Dexmedetomidine related cardiac arrest in a patient with permanent pacemaker; a cautionary tale. Pacing Clin Electrophysiol. 2007;30(9):1158–60.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Muntazar M, Kumar FC. Cardiac arrest, a preventable yet a possible risk of dexmedetomidine: fact or fiction? Anesthesiology. 2004;101(6):1478–9. author reply 9–80.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Panzer O, Moitra V, Sladen RN. Pharmacology of sedative-analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists. Crit Care Clin. 2009;25(3):451–69. vii.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Martin E, Ramsay G, Mantz J, Sum-Ping ST. The role of the alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intensive Care Med. 2003;18(1):29–41.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Bergese SD, Candiotti KA, Bokesch PM, Zura A, Wisemandle W, Bekker AY, et al. A phase IIIb, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of dexmedetomidine for sedation during awake fiberoptic intubation. Am J Ther. 2010;17(6):586–95.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II Hemodynamic changes. Anesthesiology. 1992;77(6):1134–42.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93(2):382–94.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Ingersoll-Weng E, Manecke GR Jr, Thistlethwaite PA. Dexmedetomidine and cardiac arrest. Anesthesiology. 2004;100(3):738–9.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Takata K, Adachi YU, Suzuki K, Obata Y, Sato S, Nishiwaki K. Dexmedetomidine-induced atrioventricular block followed by cardiac arrest during atrial pacing: a case report and review of the literature. J Anesth. 2014;28(1):116–20.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Bharati S, Pal A, Biswas C, Biswas R. Incidence of cardiac arrest increases with the indiscriminate use of dexmedetomidine: a case series and review of published case reports. Acta Anaesthesiol Taiwanica. 2011;49(4):165–7.CrossRefGoogle Scholar
  97. 97.
    Zhang X, Schmidt U, Wain JC, Bigatello L. Bradycardia leading to asystole during dexmedetomidine infusion in an 18 year-old double-lung transplant recipient. J Clin Anesth. 2010;22(1):45–9.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Shepard SM, Tejman-Yarden S, Khanna S, Davis CK, Batra AS. Dexmedetomidine-related atrial standstill and loss of capture in a pediatric patient after congenital heart surgery. Crit Care Med. 2011;39(1):187–9.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Karhuvaara S, Kallio A, Scheinin M, Anttila M, Salonen JS, Scheinin H. Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. Br J Clin Pharmacol. 1990;30(1):97–106.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Karhuvaara S, Kallio A, Salonen M, Tuominen J, Scheinin M. Rapid reversal of alpha 2-adrenoceptor agonist effects by atipamezole in human volunteers. Br J Clin Pharmacol. 1991;31(2):160–5.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Scheinin H, Aantaa R, Anttila M, Hakola P, Helminen A, Karhuvaara S. Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers. Anesthesiology. 1998;89(3):574–84.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Paris A, Tonner PH. Dexmedetomidine in anaesthesia. Curr Opin Anaesthesiol. 2005;18(4):412–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Simon Zec
    • 1
  • Antony Tharian
    • 1
    • 2
  • Kenneth D. Candido
    • 1
    • 2
    • 3
  • Nebojsa Nick Knezevic
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of AnesthesiologyAdvocate Illinois Masonic Medical CenterChicagoUSA
  2. 2.Department of AnesthesiologyUniversity of IllinoisChicagoUSA
  3. 3.Department of SurgeryUniversity of IllinoisChicagoUSA

Personalised recommendations